Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Current Leases (2020 - 2025)

Tango Therapeutics has reported Current Leases over the past 6 years, most recently at $2.7 million for Q4 2025.

  • Quarterly results put Current Leases at $2.7 million for Q4 2025, up 11.57% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (up 11.57% YoY), and the annual figure for FY2025 was $2.7 million, up 11.57%.
  • Current Leases for Q4 2025 was $2.7 million at Tango Therapeutics, down from $3.1 million in the prior quarter.
  • Over the last five years, Current Leases for TNGX hit a ceiling of $3.1 million in Q3 2025 and a floor of $629000.0 in Q2 2022.
  • Median Current Leases over the past 5 years was $2.1 million (2023), compared with a mean of $2.0 million.
  • Biggest five-year swings in Current Leases: fell 28.48% in 2022 and later skyrocketed 187.28% in 2023.
  • Tango Therapeutics' Current Leases stood at $1.5 million in 2021, then grew by 17.76% to $1.8 million in 2022, then rose by 17.63% to $2.1 million in 2023, then increased by 17.87% to $2.5 million in 2024, then rose by 11.57% to $2.7 million in 2025.
  • The last three reported values for Current Leases were $2.7 million (Q4 2025), $3.1 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.